Skip to content
Study details
Enrolling now

Group Retreat Psilocybin Therapy Trial

University of Washington
NCT IDNCT07336238ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

18

Study length

about 1.8 years

Ages

18–85

Locations

1 site in WA

What this study is about

This trial is testing the safety, side effects, and effectiveness of group retreat psilocybin therapy for anxiety and depression in people with advanced cancers. The treatment involves psilocybin combined with structured discussions to help patients gain new insights about their condition. This study refines a previous study that showed psilocybin therapy was safe.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Psychotherapy
  • 2.Survey Administration
  • 3.Take Psilocybin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

oral

Endpoints

Primary: Incidence of adverse events

Secondary: Symptoms of Anxiety and Depression assessed via the Hospital Anxiety and Depression Scale (HADS): Change in Mean Total score

Body systems

Psychiatry / Mental Health